Compare VALN & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALN | DSU |
|---|---|---|
| Founded | 2012 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.3M | 594.7M |
| IPO Year | 2021 | 1998 |
| Metric | VALN | DSU |
|---|---|---|
| Price | $6.69 | $9.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 81.9K | ★ 213.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $93.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $9.31 |
| 52 Week High | $12.23 | $10.61 |
| Indicator | VALN | DSU |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 38.34 |
| Support Level | $5.10 | $9.33 |
| Resistance Level | $7.31 | $9.94 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 47.78 | 9.38 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.